---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-016308"
form_type: "8-K"
ticker: "XTNT"
cik: "0001453593"
company_name: "Xtant Medical Holdings, Inc."
filed_at: "2026-04-13T23:59:59+00:00"
generated_at: "2026-05-15T06:33:50.690984+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xtant Medical secures exclusive U.S. distribution rights for HEMOBLAST Bellows hemostat

## Summary
- Paid Dilon a $5.0M exclusivity fee; no minimum purchase requirements.
- Hired approximately 20 Dilon U.S. sales personnel to commercialize the product.
- HEMOBLAST Bellows is an FDA-approved collagen/thrombin/chondroitin sulfate hemostatic powder.
- Addresses estimated $2.0 billion global addressable market for hemostatic products.
- Xtant to update FY2026 guidance upon Q1 2026 earnings release.

## SEC filing metadata
- accession: 0001493152-26-016308
- form_type: 8-K
- ticker: XTNT
- cik: 0001453593
- company_name: Xtant Medical Holdings, Inc.
- filed_at: 2026-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453593/000149315226016308/0001493152-26-016308-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453593/000149315226016308/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-016308
- JSON: https://secwatch.observer/filing/0001493152-26-016308.json
- Plain text: https://secwatch.observer/filing/0001493152-26-016308.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.